Mark Cuban Aims To Disrupt A $365 Billion Industry – With The Only Startup That Bears His Name

Billionaire venture capitalist Mark Cuban has founded or invested early in hundreds of startup companies over the years. But only one of them, founded in January 2022, bears his name.

The Mark Cuban Cost Plus Drug Co. seeks to disrupt the $365 billion U.S. prescription drug market, which is rife with pricing inefficiencies. Dozens of startups are looking to solve America’s broken healthcare system, and some are seeing substantial success doing it. For example, TruBrain is a startup developing innovative neurotechnology backed by leading venture capitalists. The startup recently launched on StartEngine, which means anyone can invest in TruBrain for a limited time. Click here to invest in TruBrain. 

Mark Cuban’s startup drastically cuts drug costs. For example, one tablet of the Type 2 diabetes treatment Metformin costs over $500 at retail prices. But through Cuban’s company, the same tablet is just $46.20. 

To stay updated with top startup news and investments, sign up for Benzinga’s Startup Investing & Equity Crowdfunding Newsletter

The company offers 350 prescription drugs at cost, plus a fixed 15% margin, making some prescription drugs significantly cheaper than their retail prices. The savings are made possible in part by eliminabeting the middleman in the prescription drug industry: Cuban’s company bypasses health insurers to negotiate directly with drug manufacturers.

The startup could have saved Medicare up to $3.6 billion in 2020 alone, according to a study by Harvard Medical School. But as significant as that number is, it pales in comparison to an even lower-hanging fruit in the fight to drive down healthcare costs: targeting the nationwide stress epidemic. 

Stress costs the U.S. economy as much as $300 billion per year, according to the American Psychological Association. A huge source of this is healthcare costs, with 65% of households reporting high levels of stress or anguish over treatment costs. Cuban’s company, should it succeed in slashing prescription drug prices across the board, could provide tremendous relief on this front.

While investors can’t invest in Mark Cuban’s startup, investors do have options. TruBrain allows investors to own a stake in their healthcare startup taking on the mental wellness space with their leading neurotechnology. Click here to invest in TruBrain. 

See more on startup investing from Benzinga.

• Collaborative Robots Startup Using Teams Of AI-Powered Drones To Make Flying Safer

• A Healthier Alternative to Coffee & Energy Drinks: Pureboost Gives You Energy Without The Burnout and Exhaustion

Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17b disclosure linked in the campaign page for more information.

TruBrain's Reg A+ offering is made available through StartEngine Primary, LLC, member FINRA /SIPC.This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view TruBrain's offering circular and risks associated with this offering.